The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 23, 2014
Filed:
Sep. 30, 2013
Applicant:
Molecular Insight Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
John W. Babich, Cambridge, MA (US);
Craig Zimmerman, Topsfield, MA (US);
John Joyal, Melrose, MA (US);
Kevin P. Maresca, Tewksbury, MA (US);
John Marquis, Nashua, NH (US);
Genliang Lu, Winchester, MA (US);
Jian-cheng Wang, Revere, MA (US);
Shawn Hillier, Danvers, MA (US);
Assignee:
Molecular Insight Pharmaceuticals, Inc., Tarrytown, NY (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/18 (2006.01); A61K 31/4192 (2006.01); A61K 31/444 (2006.01); A61K 31/555 (2006.01); A61K 51/04 (2006.01); C07D 213/38 (2006.01); A61P 1/00 (2006.01); C07D 403/12 (2006.01); C07F 13/00 (2006.01); A61K 47/22 (2006.01); A61K 49/00 (2006.01); C07C 275/16 (2006.01); C07C 311/16 (2006.01); C07D 403/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/22 (2013.01); A61K 31/4192 (2013.01); A61K 31/444 (2013.01); C07D 403/12 (2013.01); C07D 213/38 (2013.01); C07F 13/005 (2013.01); A61K 49/00 (2013.01); A61K 31/555 (2013.01); A61K 51/0474 (2013.01); A61K 51/0446 (2013.01); A61K 51/041 (2013.01); A61K 31/18 (2013.01); C07C 275/16 (2013.01); A61K 51/04 (2013.01); C07C 311/16 (2013.01); A61K 51/0478 (2013.01); A61K 51/0406 (2013.01); C07D 403/06 (2013.01);
Abstract
Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.